We speculate, based on our findings and studies in prostate cancer, that ADT response in SRD5A1 overexpressing tumors may be further enhanced by adding the SRD5A1 inhibitor dutasteride to the ADT regimen. Here, SRD5A1 is linked to prostate cancer.